DRNA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals...

Stats
Dzisiejszy wolumen	5.54M
Średni wolumen	3.03M
Kapitalizacja rynkowa	0.00
EPS	$-0.220 ( 2021-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.989 (2.59%)

Insider Trading

Date	Person	Action	Amount	type
2021-12-28	Koppel Adam	Sell	3 080 237	Common Stock
2021-12-28	Koppel Adam	Sell	3 333	Restricted Stock Units
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 12 087 \| Sell: 8 528 928

Wolumen Korelacja

Długi: 0.55 (weak)

Krótki: 0.93 (very strong)

Signal:(82.281) Expect same movement, but be aware

Dicerna Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
ORTX	0.976
ASLN	0.972
ADMS	0.97
CSII	0.969
PATI	0.968
DXPE	0.967
MIRO	0.963
GRBK	0.962
MNMD	0.961
WPRT	0.96

10 Najbardziej negatywne korelacje
CPSH	-0.981
PHCF	-0.963
CPTN	-0.96
AADI	-0.958
CARA	-0.957
STIM	-0.956
PRAA	-0.955
BRKL	-0.953
VEON	-0.948
PEBK	-0.947

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Dicerna Pharmaceuticals Korelacja - Waluta/Towar

0.67
( moderate )

-0.09
( neutral )

0.35
( neutral )

0.55
( weak )

-0.67
( moderate negative )

Dicerna Pharmaceuticals Finanse

Annual	2020
Przychody:	$164.31M
Zysk brutto:	$164.31M (100.00 %)
EPS:	$-1.520

FY	2020
Przychody:	$164.31M
Zysk brutto:	$164.31M (100.00 %)
EPS:	$-1.520

FY	2019
Przychody:	$23.90M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.760

FY	2018
Przychody:	$6.18M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.600

Financial Reports:

No articles found.

Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.